View content from previous Summit on Precision Diagnosis and Treatment of Prostate Cancer

Virtual Event

The 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical cases and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization.

The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.

View flyer here for our outstanding selected speakers and members of the Steering Committee.

The 5th Global Summit will build on the success of the previous Global Summits, which have emerged as the seminal events in recognizing the importance of a comprehensive, multimodality diagnostic evaluation (radiogenomics) and its integration with clinical decisions, including appropriate interventions and management. To learn more about the Annual Summit history and highlights, please visit here.

The scope of the Summit includes a full spectrum of patient care cycle:

  • Current and future advances in “smart screening”;
  • Diagnostic assessment of men suspected of prostate cancer (PC);
  • Selection of patients for biopsies and improved tissue sampling;
  • Improved diagnosis of localized PC and selection of patients for appropriate care (e.g., AS, image-targeted, minimally invasive interventions, or immediate standard treatment, such as radical surgery or radiation);
  • Improved early diagnosis of recurrent and advanced PC, including oligometastatic and systemic metastatic disease;
  • Expanded discussion on image-guided, minimally-invasive treatment and its clinical utility in localized, recurrent and advanced disease compared to other therapeutic interventions; and
  • Increased participation of the organizations leading training, accreditation, regulatory, and reimbursement policies to expedite clinical evaluation and adoption of promising novel diagnostics and therapeutics.

We would welcome sponsorship of the 5th Global Summit on Precision Diagnosis and Treatment for Prostate Cancer. Please review Sponsorship Levels and Sponsorship Registration Form.

If you have any questions and/or need more information regarding the planned Summit program or sponsorship, please contact our office by email ( or phone 617-523-3535.

Previous Summits




Royal Philips of the Netherlands is a diversified technology company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Philip’s commitment is to deliver new healthcare and lighting technologies, as well as innovative and locally relevant consumer products that make a real difference to our customers, consumers and stakeholders across the globe.

To learn more, please visit

Telix Pharmaceuticals mission is to help patients with cancer live longer with a better quality of life. Telix will become a global leader in the delivery of disruptive precision oncology products.

To learn more, please visit


Astellas Pharma US, Inc. is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.

Pfizer Oncology is committed to pursuing innovative treatments that are helping to redefine life with cancer. As an oncology leader with one of the most robust oncology pipelines in the industry, we are focused on translating scientific breakthroughs into clinical application. Additionally, we are dedicated to working collaboratively with the community to make a positive impact on people’s lives.

For more information, please visit:

GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE). As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook, LinkedIn, Twitter, and Insights for the latest news, or visit our website for more information.

Lantheus Holdings, Inc. is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents, targeted therapeutics and artificial intelligence to find, fight and follow disease.

To learn more, please visit

Siemens Healthineers AG is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients.


Amgen Oncology is searching for and finding answers to incredibly complex questions that will advance care and improve lives for cancer patients and their families. Our research drives us to understand the disease in the context of the patient’s life – not just their cancer journey – so they can take control of their lives.

For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company’s history, moving with great speed to advance those innovations for the patients who need them.

At Amgen, we are driven by our commitment to transform the lives of cancer patients and keep them at the center of everything we do.

For more information, follow us on

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

To learn more, please visit

miR Scientific LLC ( is a healthcare company revolutionizing cancer management with a breakthrough, proprietary discovery platform that enables accurate and early high-throughput disease characterization.

miR Scientific received FDA Breakthrough Device designation for the miR Sentinel™ Liquid Biopsy Urine Test that not only detects prostate cancer with high accuracy, but also provides information on the disease’s severity and aggressiveness, potentially allowing for more accurate, precise and effective treatment of the disease thereby optimizing the outcome of life-changing interventions and impacting the standard of care.

We aim to improve day-to-day care for patients and positively impact the cost of healthcare for payors, employers and other stakeholders worldwide.


Advanced Accelerator Applications (AAA), a Novartis company, is a medicines company developing targeted RLT and imaging radioligands in oncology. We are committed to transforming patients’ lives by leading innovation in nuclear medicine.

To learn more please visit

Blue Earth Diagnostics, a subsidiary of Bracco Imaging, is a recognized leader in the development and commercialization of novel PET radiopharmaceuticals to inform clinical management for cancer patients. Its portfolio includes a commercial product for recurrent prostate cancer and a robust pipeline of investigational agents.
For more information, visit:

Cleveland Diagnostics is developing technology to detect cancer early when it can be treated and cured.

To learn more, please visit:

Exact Imaging’s ExactVu™ 29 MHz micro-ultrasound platform provides a 300%improvement in resolution over conventional ultrasound enabling real-time targeted prostate biopsies.It is simple, affordable, and an extension of the current urological workflow. For the minority of cases where MRI might assist, theFusionVu™micro-US/MRI fusion application operates on the same platform––and is guided by the real-time 70micron resolution of the ExactVu system.

To learn more, please visit:

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.

To learn more, please visit

OPKO Health, Inc., a multi-national pharmaceutical and diagnostic company, establishes industry-leading positions through discovery and development of novel technologies, including the 4Kscore Test which provides an accurate and personalized measure of men’s risk for aggressive prostate cancer. The four kallikrein panel of biomarkers utilized in the 4Kscore Test is based on more than a decade of research conducted by scientists at Memorial Sloan-Kettering Cancer Center and leading European institutions and is included as a standard of care in the NCCN Prostate Cancer Early Detection Guidelines since 2015.

To learn more, please visit:


Hitachi Healthcare’s commitment to ultrasound for surgeons offers a wide range of consoles and specifically designed transducers to meet the needs of every surgeon. Recognized for our superior image quality, system reliability and use of cutting edge technology, we remain the standard in the field of ultrasound for surgeons.

To learn more, visit our website:

KOELIS has assisted urologists and radiologists from around the world in their routine clinical practice since 2006, providing the latest technology for personalized prostate cancer planning and management, from fusion biopsy to active surveillance and prostate treatment. Focused on developing advanced, targeted and less invasive solutions, KOELIS is committed to creating and bringing to the market a new paradigm in prostate cancer care, where physicians can offer the most personalized answers to their patients, avoiding any under or over-treatment and preserving quality of life. Thanks to cutting-edge imaging tools like KOELIS Trinity® prostate fusion biopsy system, which combines multiple imaging modalities with full 3D ultrasound and Organ-Based Tracking Fusion®, any suspicious lesion is characterized in a detailed 3D prostate map, offering a comprehensive and multi-parametric approach and enhancing diagnostic confidence.

Based in Grenoble (France), Princeton (NJ, USA) and Hong-Kong, KOELIS technology has been featured in more than 70 clinical publications and treats more than 300,000 patients worldwide, including patients in Europe, United States, Canada, Japan, Australia, South America and the Middle East.

Perineologic creates innovative products to increase patient safety and while expanding the ability of the clinicians to treat and manage their patients. Their featured product, PrecisionPoint™ Transperineal Access System, provides exquisite ultrasound guided biopsy of the prostate through the perineum rather than the rectum. This reduces the risk of infection for the patient and provides more precise access to all areas of the prostate to enhance biopsy sampling.

Visit our website to see a demonstration of the PrecisionPoint™ Access System and get information for incorporating this pioneering device into your practice.

Profound Medical’s mission is to change the standard of care, by providing customizable, incision-free ablation therapies. Profound is commercializing TULSA-PRO®, a novel technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH). TULSA-PRO® is CE marked and received 510(k) clearance from the U.S. Food and Drug Administration in August 2019.

For more information, visit their website:


The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 trillion in the search for new treatments and cures, including an estimated $83 billion in 2019 alone.

To learn more, please visit